Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 44Breast Neoplasms 30Lymphoma 29Sarcoma 27Hodgkin Disease 24Triple Negative Breast Neoplasms 20Burkitt Lymphoma 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Neoplasms 15Lymphoma, Follicular 15Ovarian Neoplasms 14Lymphoma, B-Cell 14Lymphoma, Non-Hodgkin 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, T-Cell, Peripheral 9Endometrial Neoplasms 9Neuroblastoma 7Neoplasm Metastasis 7Lymphoma, Mantle-Cell 7Liposarcoma 7Leukemia 7Fallopian Tube Neoplasms 7Recurrence 6Multiple Myeloma 6Leiomyosarcoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Osteosarcoma 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Inflammatory Breast Neoplasms 5

Interventions

Letrozole 2trametinib 1ribociclib 1niraparib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Doxorubicin 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cystadenocarcinoma, Serous × Doxorubicin × 1 year × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡